Alobresib

DRUG2 trials

Sponsors

Gilead Sciences

Conditions

Metastatic Castrate-Resistant Prostate CancerSolid Tumors and Lymphomas

Phase 1

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer

CompletedNCT02392611

Gilead SciencesSolid Tumors and Lymphomas

Start: 2015-03-16End: 2017-10-11Updated: 2020-12-29

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 (Alobresib) as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer

TerminatedNCT02607228

Gilead SciencesMetastatic Castrate-Resistant Prostate Cancer

Start: 2015-12-08End: 2019-09-03Updated: 2020-12-08